上市方式 · 2026-02-12

HKEX Stress Testing of Key Supplier Disruption Scenarios for an Applicant

The HKEX Listing Division has intensified its scrutiny of supply chain concentration risk in 2025, moving beyond static single-supplier dependency ratios to demand dynamic stress testing of key supplier disruption scenarios. This shift, codified in a series of Listing Decision LD143-2025 guidance notes, directly responds to the cascading failures observed in the global semiconductor and rare earth supply chains during the 2023-2024 trade realignment. For applicants seeking a Main Board listing, the Listing Division now expects a quantified, scenario-based analysis of how a 12-week or longer cessation of supply from a top-three supplier would impact revenue recognition, inventory valuation, and compliance with the HKEX’s continuing listing criteria under Chapter 13. The burden of proof has shifted from a narrative risk factor disclosure to a financial model stress test, requiring applicants to demonstrate a minimum 90-day operational resilience buffer—a standard derived from the HKMA’s Supervisory Policy Manual module SA-2 on operational resilience, applied by analogy to listed issuers. This article examines the mechanics of these stress tests, the regulatory framework underpinning them, and the practical implications for sponsor due diligence and prospectus drafting.

The Regulatory Mandate for Supplier Disruption Stress Testing

From Static Disclosure to Dynamic Modelling

The HKEX’s 2024 consultation paper on listing regime enhancements flagged supply chain concentration as a systemic risk requiring quantitative disclosure. Listing Decision LD143-2025 formalised this by requiring applicants with a single supplier accounting for more than 30% of cost of goods sold (COGS) or a top-three supplier concentration exceeding 60% of COGS to file a supplier disruption stress test as part of the listing application. This replaces the previous practice under Guidance Letter HKEX-GL94-18, which accepted qualitative risk factor disclosure in the prospectus.

The stress test must model three scenarios: a 4-week disruption, a 12-week disruption, and a 26-week disruption, each calibrated to the applicant’s specific industry. For example, a biotech applicant reliant on a single contract development and manufacturing organisation (CDMO) for active pharmaceutical ingredient (API) supply must model the impact on clinical trial timelines and revenue recognition under HKFRS 15. The HKEX’s Listing Division has explicitly referenced the Hong Kong Monetary Authority’s TM-G-2 (Business Continuity Planning) circular as a benchmark for scenario severity, requiring applicants to demonstrate that their modelling assumptions are at least as conservative as the HKMA’s prescribed recovery time objectives (RTOs) of 4 hours for critical functions, scaled to a 90-day operational buffer.

The 90-Day Operational Resilience Benchmark

The 90-day threshold is not arbitrary. It derives from the HKEX’s interpretation of Main Board Rule 13.24, which requires an issuer to carry on a “sufficient level of operations” to warrant continued listing. In the context of supplier disruption, the Listing Division has stated in LD143-2025 that a 12-week cessation of supply from a key supplier would, in most industries, impair the issuer’s ability to generate revenue for a period that triggers the Rule 13.24 assessment. The stress test must therefore demonstrate that the applicant can maintain at least 70% of its normalised monthly revenue for 90 consecutive days following a key supplier disruption, using alternative sourcing, inventory buffers, or contractual force majeure protections.

For applicants in the electronics manufacturing sector, where component lead times can exceed 20 weeks, the HKEX has required evidence of dual-sourcing agreements with at least two non-overlapping suppliers, each capable of supplying 50% of the disrupted volume. This requirement mirrors the SFC’s Code of Conduct for Corporate Finance Advisers (paragraph 17.1), which obliges sponsors to verify the enforceability of such agreements under the governing law of the supplier’s jurisdiction—typically the PRC, Taiwan, or Japan.

Mechanics of the Stress Test: Data Requirements and Modelling Parameters

Identifying the Key Supplier Portfolio

The stress test begins with a precise definition of “key supplier.” The HKEX’s Listing Division, in its 2025 review of listing applications, has applied a three-pronged test: (i) the supplier accounts for more than 10% of the applicant’s total purchases over the three most recent financial years; (ii) the supplier provides a component, raw material, or service that cannot be substituted within 30 days without a material adverse effect on product quality or regulatory compliance; and (iii) the supplier is the sole qualified source for a component required for regulatory approval (e.g., a drug master file holder for a pharmaceutical applicant, or a certified foundry for a semiconductor design house).

For applicants with a PRC operating entity structured through a variable interest entity (VIE) or a wholly foreign-owned enterprise (WFOE), the Listing Division has required the stress test to account for the PRC supplier’s own regulatory dependencies. This includes the supplier’s reliance on export licences under the PRC Export Control Law (effective 1 December 2020), the PRC Anti-Foreign Sanctions Law (effective 10 June 2021), and any applicable US Bureau of Industry and Security (BIS) export restrictions if the supplier’s products incorporate US-origin technology. The sponsor must obtain written confirmations from the supplier’s legal counsel in the PRC on the supplier’s ability to continue shipments during a simulated geopolitical disruption.

Financial Modelling Under HKFRS

The stress test must be modelled under Hong Kong Financial Reporting Standards (HKFRS), with specific attention to HKFRS 9 (Financial Instruments), HKFRS 15 (Revenue from Contracts with Customers), and HKAS 2 (Inventories). The Listing Division has rejected applications where the stress test used cash basis accounting or failed to recognise impairment losses on inventory that would become obsolete during a 12-week disruption.

For a typical manufacturing applicant, the model must calculate the following outputs under each disruption scenario: (i) the reduction in revenue, applying HKFRS 15’s variable consideration constraints (paragraph 56) to estimate the probability-weighted consideration that can be recognised; (ii) the impairment of raw materials and work-in-progress inventory under HKAS 2 paragraph 28, using net realisable value estimates that assume a 20% discount for distressed sales; and (iii) the impact on net current assets, which must remain above the HKEX’s implied liquidity threshold of 1.2x current ratio under the stress scenario.

The HKEX’s Listing Division has published a sample stress test template in its 2025 FAQ on supply chain disclosures, which requires applicants to show the cumulative EBITDA impact over a 12-month period following the disruption. For an applicant with HKD 500 million in annual revenue and a 40% gross margin, a 12-week disruption to a sole supplier representing 35% of COGS would typically reduce EBITDA by HKD 21 million to HKD 28 million, assuming no mitigating actions. The sponsor must then model the effect of mitigation strategies, such as drawing on a committed credit facility, and demonstrate that the applicant’s debt service coverage ratio remains above 1.5x under the most severe scenario.

Verification of Supplier Contracts and Force Majeure Clauses

The SFC’s Code of Conduct for Corporate Finance Advisers (paragraph 17.1) requires sponsors to exercise “due diligence in verifying the material facts” in a listing application. For supplier disruption stress tests, this translates into a contractual review of the top three suppliers’ master supply agreements. The sponsor must confirm that each agreement contains a force majeure clause that covers the specific disruption scenarios modelled—including pandemics, trade embargoes, and regulatory shutdowns—and that the clause does not permit the supplier to terminate without cause during the disruption period.

In practice, the Listing Division has required sponsors to obtain legal opinions from the supplier’s jurisdiction on the enforceability of force majeure clauses under the applicable civil law code. For PRC suppliers, this means an opinion under the PRC Civil Code (effective 1 January 2021), which at Article 590 defines force majeure as “objective circumstances that are unforeseeable, unavoidable, and insurmountable.” The sponsor must confirm that the simulated disruption (e.g., a US export ban on semiconductor manufacturing equipment) would meet this standard. If the supplier’s force majeure clause excludes trade sanctions, the stress test must assume the disruption is permanent, triggering a full impairment of the supplier relationship and a reassessment of the applicant’s going concern basis under HKFRS 1.

Prospectus Risk Factor Disclosure

The prospectus must include a dedicated risk factor section titled “Risks Relating to Supply Chain Concentration and Key Supplier Disruption,” which cross-references the stress test results. The HKEX’s Listing Decision LD143-2025 specifies that the risk factor must disclose: (i) the percentage of COGS attributable to the top three suppliers for each of the three most recent financial years; (ii) the results of the 12-week disruption scenario, including the estimated revenue decline, EBITDA impact, and the number of days before the applicant would breach its loan covenants; and (iii) the mitigation strategies in place, including the quantum of inventory buffer (in days of COGS) and the existence of dual-sourcing agreements.

For an applicant in the electric vehicle battery supply chain, the prospectus must also disclose the geographic concentration of its key suppliers. If 80% of a critical raw material (e.g., lithium carbonate or cobalt) is sourced from the PRC, the risk factor must cite the PRC’s 2024 export controls on battery-grade lithium and the potential for further restrictions under the PRC Export Control Law. The sponsor must include a sensitivity analysis showing the impact of a 30% price increase in the raw material, as modelled under the stress test, on the applicant’s gross margin and working capital cycle.

Practical Implications for Listing Timelines and Valuation

The introduction of supplier disruption stress tests has added 4 to 6 weeks to the sponsor due diligence timeline for applicants with high supply chain concentration. Sponsors must now engage third-party supply chain consultants to verify the applicant’s inventory data and supplier contracts, and to perform site visits to the top three suppliers’ manufacturing facilities. The HKEX’s Listing Division has rejected two applications in Q1 2025 where the sponsor’s stress test relied on management estimates without independent verification of the supplier’s production capacity.

For an applicant targeting a Main Board listing in H2 2025, the sponsor should begin the stress test modelling at least 12 weeks before the submission of the A1 application. This allows time for the Listing Division’s pre-hearing review, which now includes a dedicated session on supply chain resilience for applicants with a key supplier concentration above 40% of COGS. The HKEX’s Listing Committee has signalled that it may require a supplemental circular if the stress test reveals a material weakness in the applicant’s operational resilience, which would delay the listing by a minimum of 8 weeks.

Valuation Discounts for Concentration Risk

The disclosure of stress test results in the prospectus has a direct impact on the applicant’s valuation during the bookbuilding process. Institutional investors, particularly family offices and pension funds, have begun applying a supply chain concentration discount of 5% to 15% to the offer price, based on the severity of the disruption scenarios. For a biotech applicant with a sole-source CDMO, the discount has been observed at the higher end of this range, as investors factor in the risk of clinical trial delays and regulatory approval setbacks.

The HKEX’s Listing Division does not regulate the offer price, but the SFC’s Code of Conduct (paragraph 5.2) requires sponsors to ensure that the prospectus contains “all information necessary for a prospective investor to make an informed assessment” of the applicant’s financial position. The stress test results, if they show a material risk of revenue decline exceeding 20% under the 12-week scenario, must be presented in the “Financial Information” section of the prospectus, alongside the pro forma financial statements. This disclosure has led to downward revisions in offer prices for two Hong Kong-listed semiconductor applicants in 2025, with the final offer price set 12% below the initial indicative range.

Actionable Takeaways for Applicants and Sponsors

Begin supplier disruption stress test modelling at least 12 weeks before the A1 submission, engaging a third-party supply chain consultant to verify inventory data and supplier contract enforceability across PRC, Taiwan, and Japan jurisdictions.
Ensure the stress test models three scenarios (4-week, 12-week, and 26-week disruptions) under HKFRS, with specific attention to HKFRS 15 revenue recognition constraints and HKAS 2 inventory impairment, and demonstrate a 90-day operational resilience buffer at 70% of normalised monthly revenue.
Obtain legal opinions from the supplier’s jurisdiction on force majeure clause enforceability under the applicable civil code (e.g., PRC Civil Code Article 590), and confirm that the simulated disruption scenarios are covered without exclusion for trade sanctions or regulatory shutdowns.
Disclose the stress test results in the prospectus risk factor section with precise percentages for COGS concentration, revenue decline under the 12-week scenario, and the number of days before loan covenant breach, and include a sensitivity analysis for raw material price increases.
Prepare for a potential 5% to 15% valuation discount from institutional investors based on supply chain concentration risk, and discuss with the sponsor whether to adjust the indicative offer price range downward to reflect the disclosed stress test outcomes.